Building Bridges to Wellness: AAMWA, Al B. Sure!, and Rev. Al Sharpton Champion Genotype Testing Advocacy

WASHINGTON, D.C. –The African American Male Wellness Agency (AAMWA) is taking a leading role in a collaborative effort with R&B recording artist Al B. Sure! and Rev. Al Sharpton, who serve as the Executive Chairman and Senior Adviser of the Health Equity in Transplantation Coalition, respectively. This coalition, comprising health equity organizations, transplant patients, healthcare providers, and CareDx, is fervently rallying to reverse the cessation of genotype testing for rejected transplanted organs.

Recognizing the urgency of this critical cause, AAMWA is joining forces with Al B. Sure!, Rev Al Sharpton, and other influential figures to address the pressing need for continued access to genotype testing. The groundbreaking products Allosure and AlloMap, developed by CareDx, specialize in transplant care, significantly enhancing the viability and minimizing the risk of rejection. Genotype testing plays a crucial role in assisting healthcare providers in managing care maintenance for patients who have undergone heart, lung, and kidney transplants.

Given the disproportionate risk of organ rejection faced by Black and Brown Americans, sustaining coverage for genotype testing is crucial. This testing is essential for improving the quality of life for those who have undergone life-saving transplants. Detecting rejection in advance, sometimes up to 3 months before a full rejection, is paramount. Full rejection not only leads to increased mortality but also necessitates the need for another life-saving transplant.

AAMWA has garnered support from influential lawmakers. Senator Kristen Gillibrand and Congresswoman Yvette Clarke, along with other representatives from the Black Caucus, have wholeheartedly embraced AAMWA’s mission. Recognizing the urgency of the matter, Senator Gillibrand and Congresswoman Clarke have pledged to work closely with AAMWA and other coalition members to prepare for necessary hearings and communications with the Centers for Medicare & Medicaid Services (CMS). The focus will be on advocating for bill articles and fee schedule changes that safeguard the continuation of genotype testing for transplant patients.

AAMWA and its collaborators are committed to ensuring equitable access to life-saving technologies and fostering a healthier future for African American males and, by extension, all Americans.